A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.

被引：0
|
作者：
Sekeres, MA [1 ]
Fu, AZ [1 ]
Maciejewski, JP [1 ]
Golshayan, AR [1 ]
Kalaycio, M [1 ]
Kattan, MW [1 ]
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2533
引用
收藏
页码：711A / 711A
页数：1
相关论文
共 50 条
  • [1] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Fu, Alex Z.
    Maciejewski, Jaroslaw R.
    Golshayan, Ali-Reza
    Kalaycio, Matt E.
    Kaftan, Michael W.
    CANCER, 2007, 109 (06) : 1125 - 1132
  • [2] Treatment of low-risk myelodysplastic syndromes
    Santini, Valeria
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 462 - 469
  • [3] Efficacy of growth factors compared to chemotherapy in low-risk myelodysplastic syndromes.
    Golshayan, A
    Fu, AZ
    Kattan, MW
    Brown, S
    Maciejewski, JP
    Sekeres, MA
    BLOOD, 2005, 106 (11) : 713A - 714A
  • [4] rHuEpo treatment in low-risk myelodysplastic syndromes
    Grossi, A
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 574 - 574
  • [5] Amifostine in the treatment of low-risk myelodysplastic syndromes
    Grossi, A
    Fabbri, A
    Santini, V
    Leoni, F
    Nozzoli, C
    Longo, G
    Pagliai, G
    Ciolli, S
    Ferrini, PR
    HAEMATOLOGICA, 2000, 85 (04) : 367 - 371
  • [6] Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes.
    Killick, S
    Marsh, JCW
    Cavenagh, J
    Mijovic, A
    Mufti, G
    Gordon-Smith, EC
    Bowen, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 69 - 69
  • [7] Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes.
    Killick, SB
    Marsh, JC
    Cavenagh, JD
    Mijovic, A
    Mufti, G
    Gordon-Smith, EC
    Bowen, DT
    BLOOD, 1999, 94 (10) : 306A - 307A
  • [8] Current treatment strategies in low-risk myelodysplastic syndromes
    Giagounidis, Aristoteles A. N.
    Germing, Ulrich
    Aul, Carlo
    CANCER TREATMENT REVIEWS, 2007, 33 : S19 - S24
  • [9] Survivin is overexpressed in low risk myelodysplastic syndromes.
    Cortelezzi, A
    Fracchiolla, NS
    Gianelli, U
    Caterina, P
    Lorenza, MM
    Silvano, B
    BLOOD, 2003, 102 (11) : 914A - 915A
  • [10] New aspects of the treatment of patients with low-risk myelodysplastic syndromes
    Hofmann, WK
    Seipelt, G
    Kalina, U
    Hoelzer, D
    ONKOLOGIE, 2000, 23 (01): : 12 - 16
12345